Omada Health is demonstrating a compelling growth inflection, with Q2 2026 revenue surging 43.1% year-over-year to $87.8M and gross margin expanding to 72.6%, signaling strong demand and improving cost discipline. The company achieved its first positive operat...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.15+141.2% vs $0.06 | $88M+9.7% vs $80M |
Q2 2026 May 7, 2026 | $0.01+112.5% vs -$0.08 | $78M+5.3% vs $74M |
Q2 2026 Mar 5, 2026 | $0.13+333.3% vs $0.03 | $76M+8.0% vs $70M |
Q4 2025 Nov 6, 2025 | -$0.06+40.0% vs -$0.10 | $68M-1.5% vs $69M |
The transaction represented 3% of the insider's direct equity holdings before the filing. The sale was conducted directly through an open-market transaction under a pre-established Rule 10b5-1 trading plan.
Omada Health, Inc. (OMDA) Analyst/Investor Day Transcript
SAN FRANCISCO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, will present its long-term financial targets at the company's inaugural Investor Day, being held today at the Four Seasons Hotel in New York, New York.
SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, announced a new, independent cost savings model that examined the measurable clinical and economic value of Omada's GLP-1 program.1 GlobalData , a data analytics and consulting company, recently published a report estimating greater disease reduction and higher cumulative cost savings with Omada's GLP-1 solutions compared to standard care.
Benchmark OMDA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Omada Health (OMDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.41 | $1.21B | -92.77 | 53.24% | -4.91% | -8.68% | — | |
| $29.30 | $6.54B | 57.45 | 59% | -5.51% | -30.03% | — | |
| $15.92 | $1.84B | -13.05 | 8.28% | -21.25% | -44% | — | |
| $5.67 | $1.02B | -4.97 | -1.54% | -7.13% | -13.08% | — | |
| $8.39 | $157.44M | 31.07 | 18.78% | 4.66% | 3.6% | — | |
| $3.27 | $1.13B | 38.34 | 0.57% | 2.07% | 2.61% | — |
Omada Health (OMDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Omada Health (OMDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 16, 2026·SEC
May 7, 2026·SEC
Mar 6, 2026·SEC
Get notified when OMDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Omada Health (OMDA) stock FAQ — growth, dividends, profitability & financials explained
Omada Health (OMDA) reported $309.8M in revenue for fiscal year 2025. This represents a 247% increase from $89.2M in 2022.
Omada Health (OMDA) grew revenue by 53.2% over the past year. This is strong growth.
Yes, Omada Health (OMDA) is profitable, generating $4.3M in net income for fiscal year 2025 (-4.9% net margin).
Omada Health (OMDA) has a return on equity (ROE) of -8.7%. Negative ROE indicates the company is unprofitable.
Omada Health (OMDA) generated $22.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
